Genomics from LCCC1525: A Priming Dose of Cyclophosphamide Prior to Pembrolizumab to Treat mTNBC

AFFECTION_STATUS - Case control status of the subject for breast cancer (phv00528078.v1.p1)

ANALYTE_TYPE - Analyte Type (phv00528081.v1.p1)
BODY_SITE - Body site where sample was collected (phv00528080.v1.p1)
CONSENT - Consent group as determined by DAC (phv00528073.v1.p1)
IS_TUMOR - Tumor status (phv00528082.v1.p1)
SAMPLE_ID - Sample ID (phv00528079.v1.p1)
SAMPLE_ID - Sample ID (phv00528076.v1.p1)
SUBJECT_ID - Subject ID (phv00528072.v1.p1)
SUBJECT_ID - Subject ID (phv00528075.v1.p1)
SUBJECT_ID - Subject ID (phv00528077.v1.p1)
TREATMENT_RESPONSE - Best response to TUMOR_TREATMENT as determined by investigators (End of treatment is any point after last treatment; Pre & C1D1 are prior to first treatment) (phv00528084.v1.p1)
TREATMENT_TIMEPOINT - Time of sample collection in relation to treatment schedule (phv00528083.v1.p1)